Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Yiu-Lian Fong

Yiu-Lian Fong

Director
Johnson & Johnson Innovations
United Kingdom

Biography

Yiu-Lian is the Innovation Lead for Diagnostics, at Johnson & Johnson Innovation, London. Prior to joining Johnson & Johnson Innovation, Yiu-Lian was Divisional Vice President for R&D at Abbott Molecular. In this position, she was responsible for R&D strategic oversight, menu expansion, and the development of next generation molecular diagnostic platform technologies. Previously, she was the Executive Director of Molecular Diagnostics and Companion Diagnostics Development at Novartis Oncology. Yiu-Lian brings a broad and extensive background in the pharmaceutical and biotechnology industries including experience in technology and product development, blood testing/screening, vaccines and IVD Immuno and molecular diagnostics, as well as therapeutic drug/vaccine development.

Research Interest

•Develop and/or execute business strategies for genetics, oncology, infectious disease, metabolic disease, and neuroscience •Develop and drive technical strategies for drug and companion diagnostics co-development • Recruit and develop talents, build functional departments and project teams, develop and implement product development and project management tools and processes, grow organization. • Direct, manage and oversee R&D functions for biological drug and vaccine development, blood screening, and IVD product development: Biomarker Development, Assay Development, System and SW Engineering, System Integration, Design Transfer, Technology Transfer, Technology Development, Process Development and Validation, Pilot Production, Analytical Method Development and Method Validation, QC Testing, Project Management (PMO) and Scientific Affairs. •Drug development CMC lead or core team member: Phase I, II and III IND, and NDA/BLA submissions for biological and blood screening. •Technology assessments and strategic alignment for M&A and BDL initiatives •Strategic alliance with partners and vendors, drive and manage collaborations